Endothelin-1 receptor drives invadopodia: Exploiting how β-arrestin-1 guides the way.
Metastatization is a complex multistep process requiring fine-tuned regulated cytoskeleton re-modeling, mediated by the cross-talk of actin with interacting partners, such as the Rho GTPases. Our expanding knowledge of invadopodia, small invasive membrane protrusions composed of a core of F-actin, actin regulators and actin-binding proteins, and hotspots for secretion of extracellular matrix (ECM) proteinases, contributes to clarify critical steps of the metastatic program. Growth factor receptors and their intermediate signaling molecules, along with matrix adhesion and rigidity, pH and hypoxia, act as drivers of cytoskeleton changes and invadopodia formation. We recently pro-posed a novel route map by which cancer cells regulates invadopodia dynamics supporting metastasis as response to the endothelin A receptor (ETAR), among the highly druggable G-protein coupled receptors in cancer. The metastatic behavior exhibited by ovarian cancer cells overe-xpressing ETAR is now explained by the interplay with β-arrestin1 (β-arr1), a scaffold protein acting as signal-integrating module of RhoC and cofilin signaling for specific invadopodia formation, accomplished by its interaction with a Rho guanine nucleotide exchange factor (GEF), PDZ-RhoGEF, in a G-protein independent manner. Here, we summarize this novel activation of the RhoC pathway from ETAR/β-arr1 signaling that may be exploited therapeutically and discuss new perspectives for future directions of investigations.
a Preclinical Models and New Therapeutic Agents Unit, Translational Research Functional Departmental Area , Regina Elena National Cancer Institute , Rome , Italy.
Anna
A
Bagnato
a Preclinical Models and New Therapeutic Agents Unit, Translational Research Functional Departmental Area , Regina Elena National Cancer Institute , Rome , Italy.
Laura
L
Rosanò
D006801:Humans; D000069261:Podosomes / Q000378:metabolism*; D044022:Receptor, Endothelin A / Q000378:metabolism*; D000071559:beta-Arrestin 1 / Q000378:metabolism*
D044022:Receptor, Endothelin A; D000071559:beta-Arrestin 1
G-protein coupled receptors; PDZ-RHOGEF; RhoC; cancer; endothelin; endothelin receptors; invadopodia; β-arrestin-1
Small GTPases. 2014;5:e28195
24967648
Cell Adh Migr. 2014;8(3):256-62
24727371
J Cell Sci. 2012 Feb 1;125(Pt 3):724-34
22389406
Oncogene. 2015 Aug 20;34(34):4531-44
25486435
Cancer Res. 2005 Dec 15;65(24):11649-57
16357176
Am J Physiol Regul Integr Comp Physiol. 2016 Mar 15;310(6):R469-75
26818060
Cell Signal. 2014 Sep;26(9):1935-42
24863882
Nat Rev Cancer. 2013 Sep;13(9):637-51
23884378
Nat Cell Biol. 2002 Aug;4(8):547-55
12105416
Cancer Cell. 2011 Mar 8;19(3):372-86
21397860
Cell Adh Migr. 2014;8(3):246-55
24717190
Oncogene. 2013 Oct 17;32(42):5066-77
23208497
Nat Rev Cancer. 2003 Dec;3(12):921-30
14737122
J Biol Chem. 1999 Feb 26;274(9):5868-79
10026210
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11
19202075
Cancer Lett. 2015 Jan 28;356(2 Pt B):382-91
25451317
Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
21697900
J Cell Sci. 2009 Sep 1;122(Pt 17):3037-49
19692590
Eur J Cell Biol. 2011 Feb-Mar;90(2-3):100-7
20605056
Mol Pharmacol. 2011 Nov;80(5):760-8
21836019
J Biol Chem. 2005 Mar 4;280(9):8041-50
15611106
Cancer Res. 2010 Jun 1;70(11):4634-43
20484039
Mol Biol Cell. 2014 Jan;25(1):17-29
24196838
Mol Cell Biol. 2006 May;26(9):3432-45
16611986
J Biol Chem. 2013 Apr 26;288(17):12232-43
23467409
J Biol Chem. 2016 Feb 26;291(9):4323-33
26740622
Mol Pharmacol. 2015 Oct;88(4):624-39
25808930
Mol Cancer Res. 2009 Jul;7(7):1064-77
19609003
Elife. 2014 Jun 20;3:null
24950964
Nat Rev Mol Cell Biol. 2016 Aug;17 (8):496-510
27301673
J Cell Biol. 2015 Feb 2;208(3):331-50
25646088
Mol Cell Biol. 2011 Mar;31(5):1066-75
21173159
Oncogene. 2016 Jun 30;35(26):3432-42
26522724
Cell Commun Adhes. 2014 Aug;21(4):207-12
24930891
J Cell Biol. 2012 Apr 30;197(3):421-37
22529104
J Exp Clin Cancer Res. 2016 Jul 29;35(1):121
27473335
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15299-304
20686112
J Proteomics. 2013 Mar 27;80:91-106
23313222
J Cell Physiol. 2011 Feb;226(2):559-71
20717968
Tumour Biol. 2016 May;37(5):6775-85
26662305
Trends Biochem Sci. 2011 Sep;36(9):457-69
21764321
J Biol Chem. 2010 May 7;285(19):14318-29
20207744
Mol Pharmacol. 2014 Sep;86(3):252-62
24958816
Curr Biol. 2011 Apr 26;21(8):635-44
21474314